tiprankstipranks
Trending News
More News >

Unicycive Therapeutics initiated with a Buy at Lucid Capital

Lucid Capital analyst Elemer Piros initiated coverage of Unicycive Therapeutics (UNCY) with a Buy rating and $12 price target The company could launch oxylanthanum carbonate in the second half of 2025, one of the first innovative products in over a decade for the treatment of hyperphosphatemia, the analyst tells investors in a research note. The firm says Unicycive is building a “comprehensive” drug portfolio for chronic kidney disease and acute kidney injury.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue